Use of allogeneic scaffold-free chondrocyte pellet in repair of osteochondral defect in a rabbit model

Cell‐based therapies are currently being used in treating osteochondral defect (OCD), but technical advances are needed to tackle the problems of scaffold and grafting technique. This study aimed to test the potential of allogeneic scaffold‐free bioengineered chondrocyte pellet (BCP) in treating OCD...

Full description

Saved in:
Bibliographic Details
Published inJournal of orthopaedic research Vol. 29; no. 9; pp. 1343 - 1350
Main Authors Cheuk, Yau-Chuk, Wong, Margaret Wan-Nar, Lee, Kwong-Man, Fu, Sai-Chuen
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.09.2011
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cell‐based therapies are currently being used in treating osteochondral defect (OCD), but technical advances are needed to tackle the problems of scaffold and grafting technique. This study aimed to test the potential of allogeneic scaffold‐free bioengineered chondrocyte pellet (BCP) in treating OCD. BCP was fabricated from rabbit costal cartilage and implanted into 3 mm × 3 mm OCD in medial femoral condyle of 20 rabbits. Samples were harvested at 2, 4, 8, and 16 weeks for histology, histological scoring and histomorphometric analysis. At treated side, cartilage score was significantly better at week 4 (p = 0.027), and cartilage thickness measured in histomorphometric analysis was significantly thicker at week 4 (p = 0.028) and week 16 (p = 0.028) compared to the empty controls. At treated side, bone score remained significantly lower from week 8 onwards (p = 0.024 at week 8, p = 0.02 at week 16) whereas bone area was significantly smaller from week 4 onwards compared to the empty controls (p = 0.028 at week 4, 8, 16). No immunorejection was observed throughout the experiment. The results demonstrated that the BCP enhanced cartilage repair at early stage. Press‐fitting of allogeneic BCP was a simple method for OCD repair without immunorejection. Further optimization of the treatment is required before clinical application. © 2011 Orthopaedic Research Society Published by Wiley Periodicals, Inc. J Orthop Res 29: 1343–1350, 2011
Bibliography:istex:E914B6C5B3D6558FA5030694BFEFD91EAF7E08BD
ark:/67375/WNG-83LD1QN6-7
ArticleID:JOR21339
Part of the content in this paper has been presented in the 54th Annual Meeting of the Orthopaedic Research Society held in San Francisco, CA, March 2-5, 2008.
The authors declare no conflict of interest related to this study.
Part of the content in this paper has been presented in the 54th Annual Meeting of the Orthopaedic Research Society held in San Francisco, CA, March 2–5, 2008.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0736-0266
1554-527X
1554-527X
DOI:10.1002/jor.21339